Naxan (Naloxone Hydrochloride)

Naloxone works as a competitive antagonist at mu‑opioid receptors in the central nervous system. By binding to these receptors without activating them, it pushes opioid agonists off the receptor sites, quickly halting their pharmacologic actions. This blockade restores normal neuronal signaling, leading to the rapid reversal of respiratory depression, sedation, and other opioid‑induced effects.

The dose of Naxan is determined by the prescribing clinician based on the severity of the opioid overdose, the patient’s age, weight, and clinical response. Standard emergency protocols often start with an initial dose, followed by additional doses if needed, but the exact regimen must be individualized and documented by a qualified healthcare professional.

The safety of naloxone hydrochloride in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should assess each case carefully and consider alternative treatments when appropriate.

To order Naxan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details—including any cold‑chain requirements—and assists with import documentation.

Naxan (naloxone hydrochloride) is chemically identical to other naloxone products but is supplied as a sterile injectable solution for IM, IV, or SC administration. Compared with auto‑injector devices, Naxan offers flexibility in dosing and route selection, which can be advantageous in controlled clinical environments. All formulations share the same mechanism of action and rapid onset of action.

Naxan should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the vials from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the product. Maintaining proper storage conditions helps preserve potency and sterility for emergency use.

Naxan is administered by a qualified healthcare professional via intramuscular, intravenous, or subcutaneous injection. The route is chosen based on the clinical situation and available access. Injection sites should be cleaned with an antiseptic, and the correct technique must be followed to ensure rapid absorption and effective reversal of opioid toxicity.

The most serious risks include precipitated acute withdrawal, which can cause severe agitation, hypertension, tachycardia, or seizures, especially in opioid‑dependent individuals. Rare but life‑threatening reactions such as anaphylaxis, pulmonary edema, or cardiac arrest have been reported. Continuous monitoring after administration is essential to detect and manage these events promptly.

Naxan is contraindicated in patients with known hypersensitivity to naloxone or any of its excipients. It should also be avoided in individuals without confirmed opioid exposure, as unnecessary antagonism can induce withdrawal symptoms. Clinical judgment is required for patients with severe cardiovascular disease, where rapid hemodynamic changes may pose additional risks.